Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 16, 2017 - Issue 7
Submit an article Journal homepage
1,362
Views
28
CrossRef citations to date
0
Altmetric
Review

A safety assessment of biological therapies targeting the IL-23/IL-17 axis in inflammatory bowel diseases

Bram VerstocktTranslational Research in Gastrointestinal Disorders (TARGID), Department of Clinical and Experimental Medicine, KU Leuven, Leuven, Belgium;Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, BelgiumORCID Iconhttp://orcid.org/0000-0003-3898-7093View further author information
ORCID Icon,
Barbara DeleenheerDepartment of Pharmaceutical and Pharmacological Sciences, Clinical Pharmacology and Pharmacotherapy, University Hospitals Leuven, KU Leuven, Leuven, BelgiumView further author information
,
Gert Van AsscheTranslational Research in Gastrointestinal Disorders (TARGID), Department of Clinical and Experimental Medicine, KU Leuven, Leuven, Belgium;Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, BelgiumView further author information
,
Séverine VermeireTranslational Research in Gastrointestinal Disorders (TARGID), Department of Clinical and Experimental Medicine, KU Leuven, Leuven, Belgium;Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, BelgiumORCID Iconhttp://orcid.org/0000-0001-9942-3019View further author information
ORCID Icon &
Marc FerranteTranslational Research in Gastrointestinal Disorders (TARGID), Department of Clinical and Experimental Medicine, KU Leuven, Leuven, Belgium;Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, BelgiumCorrespondence[email protected]
View further author information
Pages 809-821 | Received 31 Mar 2017, Accepted 31 May 2017, Published online: 09 Jun 2017

Citations (28)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Giuseppe Lopalco, Donato Rigante, Antonio Lopalco, Giacomo Emmi, Vincenzo Venerito, Antonio Vitale, Giovanna Capozio, Nunzio Denora, Luca Cantarini & Florenzo Iannone. (2020) Safety of systemic treatments for Behçet’s syndrome. Expert Opinion on Drug Safety 19:10, pages 1269-1301.
Read now
Alen Zabotti, Delia Goletti, Ennio Lubrano & Fabrizio Cantini. (2020) The impact of the interleukin 12/23 inhibitor ustekinumab on the risk of infections in patients with psoriatic arthritis. Expert Opinion on Drug Safety 19:1, pages 69-82.
Read now
Sare Verstockt, Bram Verstockt & Séverine Vermeire. (2019) Oncostatin M as a new diagnostic, prognostic and therapeutic target in inflammatory bowel disease (IBD). Expert Opinion on Therapeutic Targets 23:11, pages 943-954.
Read now
Kevin K. Veverka & Steven R. Feldman. (2018) Chronic mucocutaneous candidiasis: what can we conclude about IL-17 antagonism?. Journal of Dermatological Treatment 29:5, pages 475-480.
Read now

Articles from other publishers (24)

Selina Gies, Patrick Melchior, Russalina Stroeder, Tanja Tänzer, Laura Theobald, Maike Pohlers, Birgit Glombitza, Martina Sester, Erich‐Franz Solomayer & Barbara Walch‐Rückheim. (2023) Immune landscape of vulvar cancer patients treated with surgery and adjuvant radiotherapy revealed restricted T cell functionality and increased IL‐17 expression associated with cancer relapse. International Journal of Cancer 154:2, pages 343-358.
Crossref
Maike Pohlers, Selina Gies, Tanja Taenzer, Russalina Stroeder, Laura Theobald, Nicole Ludwig, Yoo‐Jin Kim, Rainer Maria Bohle, Erich Franz Solomayer, Eckart Meese, Martin Hart & Barbara Walch‐Rückheim. (2023) Th17 cells target the metabolic miR ‐142‐5p–succinate dehydrogenase subunit C/D ( SDHC / SDHD ) axis, promoting invasiveness and progression of cervical cancers . Molecular Oncology.
Crossref
Zhiqin Fang, Hongyin Sun, Yutong Wang, Zhenliang Sun & Mingzhu Yin. (2023) Discovery of WD-890: A novel allosteric TYK2 inhibitor for the treatment of multiple autoimmune diseases. Biomedicine & Pharmacotherapy 167, pages 115611.
Crossref
Zhimeng Lv, Ming Guo, Xuelin Zhao, Yina Shao, Weiwei Zhang & Chenghua Li. (2022) IL-17/IL-17 Receptor Pathway–Mediated Inflammatory Response in Apostichopus japonicus Supports the Conserved Functions of Cytokines in Invertebrates . The Journal of Immunology 208:2, pages 464-479.
Crossref
S.P. Déo-Gracias Berry, Camille Dossou, Ali Kashif, Niusha Sharifinejad, Gholamreza Azizi, Haleh Hamedifar, Araz Sabzvari & Zeineb Zian. (2022) The role of IL-17 and anti-IL-17 agents in the immunopathogenesis and management of autoimmune and inflammatory diseases. International Immunopharmacology 102, pages 108402.
Crossref
Laura Theobald, Russalina Stroeder, Patrick Melchior, Ioan Iulian Iordache, Tanja Tänzer, Meike Port, Birgit Glombitza, Stefanie Marx, David Schub, Christian Herr, Martin Hart, Nicole Ludwig, Eckart Meese, Yoo‐Jin Kim, Rainer Maria Bohle, Sigrun Smola, Christian Rübe, Erich Franz Solomayer & Barbara Walch‐Rückheim. (2021) Chemoradiotherapy‐induced increase in Th17 cell frequency in cervical cancer patients is associated with therapy resistance and early relapse. Molecular Oncology 15:12, pages 3559-3577.
Crossref
Rameshwar R. RaoFataneh MajlessipourDavid A. ZiringNicole M. Baca. (2021) Ewing's Sarcoma in a Patient with Crohn's Disease Treated with Ustekinumab: A Case Report. Journal of Adolescent and Young Adult Oncology 10:5, pages 614-617.
Crossref
Keiichi Tominaga, Takanao Tanaka, Mimari Kanazawa, Shoko Watanabe, Rena Nemoto, Keiichiro Abe, Akira Kanamori, Akira Yamamiya, Kenichi Goda, Yoshitomo Kushima, Kazuyuki Chibana, Taito Masawa, Tomohiro Fukuda, Toshifumi Hibi & Atsushi Irisawa. (2021) A Case of Crohn’s Disease with Cardiac Tamponade Caused by Tuberculous Pericarditis: Assessment of a Rare Phenomenon. Healthcare 9:6, pages 695.
Crossref
Hiroshi Nakase, Motoi Uchino, Shinichiro Shinzaki, Minoru Matsuura, Katsuyoshi Matsuoka, Taku Kobayashi, Masayuki Saruta, Fumihito Hirai, Keisuke Hata, Sakiko Hiraoka, Motohiro Esaki, Ken Sugimoto, Toshimitsu Fuji, Kenji Watanabe, Shiro Nakamura, Nagamu Inoue, Toshiyuki Itoh, Makoto Naganuma, Tadakazu Hisamatsu, Mamoru Watanabe, Hiroto Miwa, Nobuyuki Enomoto, Tooru Shimosegawa & Kazuhiko Koike. (2021) Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. Journal of Gastroenterology 56:6, pages 489-526.
Crossref
B. S. Belov, N. V. Muravyova, M. M. Baranova & T. V. Korotaeva. (2020) Problem of comorbid infections in patients with psoriatic arthritis. Medical alphabet:15 (2020), pages 22-28.
Crossref
Ayse Serap Karadag, Melek Aslan Kayıran, Torello Lotti & Uwe Wollina. (2020) Immunosuppressive and immunomodulator therapy for rare or uncommon skin disorders in pandemic days. Dermatologic Therapy 33:5.
Crossref
Natália S.F. Queiroz & Miguel Regueiro. (2020) Safety considerations with biologics and new inflammatory bowel disease therapies. Current Opinion in Gastroenterology 36:4, pages 257-264.
Crossref
Chunlei Sun & Jianxin Xia. (2020) Treatment of psoriasis: janus kinases inhibitors and biologics for the interleukin-23/Th17 axis. Minerva Medica 111:3.
Crossref
Maurizio Benucci, Valentina Grossi, Mariangela Manfredi, Arianna Damiani, Maria Infantino, Paolo Moscato, Luigi Cinquanta, Elisa Gremese, Barbara Tolusso, Luca Petricca, Anna Laura Fedele, Stefano Alivernini, Fabiola Atzeni, Giovanni Minisola & Roberto Verna. (2020) Laboratory Monitoring of Biological Therapies in Rheumatology: The Role of Immunogenicity. Annals of Laboratory Medicine 40:2, pages 101-113.
Crossref
Yongyu Chen, Yan Chen, Pan Cao, Wenhao Su, Na Zhan & Weiguo Dong. (2019) Fusobacterium nucleatum facilitates ulcerative colitis through activating IL‐17F signaling to NF‐κB via the upregulation of CARD3 expression . The Journal of Pathology 250:2, pages 170-182.
Crossref
Ted George Achufusi, Prateek S. Harnee & Sekou Rawlins. (2019) A Rare Case of New-Onset Ulcerative Colitis following Initiation of Secukinumab. Case Reports in Medicine 2019, pages 1-5.
Crossref
Bram Verstockt, Erwin Dreesen, Maja Noman, An Outtier, Nathalie Van den Berghe, Isolde Aerden, Griet Compernolle, Gert Van Assche, Ann Gils, Séverine Vermeire & Marc Ferrante. (2019) Ustekinumab Exposure-outcome Analysis in Crohn’s Disease Only in Part Explains Limited Endoscopic Remission Rates. Journal of Crohn's and Colitis 13:7, pages 864-872.
Crossref
A. Tsentemeidou, E. Sotiriou, E. Vakirlis, N. Sideris, I. Papadimitriou, E. Lazaridou & D. Ioannides. (2019) Real-life efficacy and safety of secukinumab: results from a tertiary hospital in Greece. Journal of the European Academy of Dermatology and Venereology 33:2, pages e50-e51.
Crossref
Gerardo Di Scala, Alessandra Bettiol, Rafaela Diana Cojan, Martina Finocchi, Elena Silvestri & Giacomo Emmi. (2019) Efficacy of the anti-IL 17 secukinumab in refractory Behçet's syndrome: A preliminary study. Journal of Autoimmunity 97, pages 108-113.
Crossref
Annick Moens, Karen van Hoeve, Evelien Humblet, Jean-François Rahier, Peter Bossuyt, Sophie Dewit, Denis Franchimont, Elisabeth Macken, Jochen Nijs, Annelies Posen, Beatrijs Strubbe, Anneleen Van Hootegem, Wouter Van Moerkercke, Séverine Vermeire & Marc Ferrante. (2019) Outcome of Pregnancies in Female Patients With Inflammatory Bowel Diseases Treated With Vedolizumab. Journal of Crohn's and Colitis 13:1, pages 12-18.
Crossref
Sanja Dragasevic, Biljana Stankovic, Aleksandra Sokic-Milutinovic, Tomica Milosavljevic, Tamara Milovanovic, Snezana Lukic, Sanja Srzentic Drazilov, Kristel Klaassen, Nikola Kotur, Sonja Pavlovic & Dragan Popovic. (2018) Importance of TLR9-IL23-IL17 axis in inflammatory bowel disease development: Gene expression profiling study. Clinical Immunology 197, pages 86-95.
Crossref
Bram Verstockt, Marc Ferrante, Séverine Vermeire & Gert Van Assche. (2018) New treatment options for inflammatory bowel diseases. Journal of Gastroenterology 53:5, pages 585-590.
Crossref
Álvaro Machado & Tiago Torres. (2018) Guselkumab for the Treatment of Psoriasis. BioDrugs 32:2, pages 119-128.
Crossref
Curdin Conrad & Michel Gilliet. (2018) Psoriasis: from Pathogenesis to Targeted Therapies. Clinical Reviews in Allergy & Immunology 54:1, pages 102-113.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.